** Shares of drug developer Capricor Therapeutics CAPR.O fall 14.12% to $10.19
** CAPR says FDA has confirmed its intent to hold an advisory committee meeting to discuss co's experimental cell therapy
** Says an official date has not yet been set
** Co is seeking approval for its therapy, deramiocel, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy
** DMD cardiomyopathy is a heart muscle complication that can develop in individuals with the genetic condition that causes progressive muscle weakness
** "We believe deramiocel remains on track to be approved with the requested label, and believe today's share weakness is unwarranted" - H.C. Wainwright analyst Joseph Pantginis
** FDA set to make decision by August 31
** Up to last close, stock down ~24% YTD
(Reporting by Sriparna Roy and Siddhi Mahatole in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。